KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.9100
+0.0600 (+7.06%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.8500
Open0.8500
Bid0.8900 x 0
Ask0.9100 x 0
Day's Range0.8400 - 0.9100
52 Week Range0.7900 - 4.3500
Volume367,259
Avg. Volume507,484
Market Cap103.657M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • CNW Group

    Khiron Receives Approval to Sell Aceso™ Hemp CBD Brand in Colombia

    First Hemp CBD brand to enter Latin American market under Dixie Brands joint venture Builds on proven Aceso brand acceptance across US consumer market Product line includes indication-specific (heat and ...

  • CNW Group

    Khiron Enters First Latin American Cannabis Lines of Research Targeting U.S. $44 Billion Dermatological Drug Market

    Lines of research presented November 2, 2019 at II TeraCILAD dermatological conference with more than 1,000 LATAM dermatologists in attendance. Global dermatological (prescription) drug market valued at $38.4bn in 2017, rising to $44.1bn in 2018 (Source:GMR Data).

  • CNW Group

    Khiron Appoints Veteran Independent Director Deborah Rosati FCPA, FCA, ICD.D

    TORONTO, Nov. 4, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announces that Mark Monaghan has resigned as a director of the Company and that Deborah Rosati FCPA, FCA, ICD.D has been appointed effective immediately to the Board of Directors of the Company. Ms. Rosati has over 30 years of experience in leading and managing high growth companies and joins the Board, effective immediately.

  • CNW Group

    Khiron To Participate in Cowen 2nd Annual Boston Cannabis Conference

    TORONTO, Nov. 1, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce its participation in the Cowen 2nd Annual Boston Cannabis Conference, taking place Tuesday, November 12th to Wednesday, November 13th, 2019 in Boston, MA.

  • CNW Group

    Khiron to Host Live Investor Webcast on November 5, 2019

    TORONTO, Oct. 31, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce that Khiron President, Chris Naprawa, will present live at Grit Capital's Webcast Series on November 5th, 2019 at 11:00am ET/8:00am PT. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.

  • Kuida is One Year Old! First Export to the US market, UK Product Approval, and 300+ Points of Sale in Colombia
    CNW Group

    Kuida is One Year Old! First Export to the US market, UK Product Approval, and 300+ Points of Sale in Colombia

    TORONTO, Oct. 25, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that, after a successful first year in the Colombian market, the Company adds another significant milestone: its first import of Kuida cosmetic products into the United States. With this first shipment complete, Kuida has become the first Colombian brand to introduce legal CBD products in the US market.

  • CNW Group

    Khiron Participates in Mexican Senate Cannabis Regulation Forum

    Mexico poised to become the largest market in the world to fully legalize cannabis nationwide Forum with industry leaders to guide legislation to legalize both adult-use and medical cannabis in Mexico ...

  • CNW Group

    Khiron to Commercialize Kuida® Brand in U.K.

    Kuida is the first CBD skincare portfolio of products launched in Colombia from a federally approved cannabis company Company has fulfilled E.U. cosmetic product regulatory requirements for seven Kuida® ...

  • CNW Group

    Khiron to Participate at BMO & TMX Hemp & Medical Cannabis Conference in London, UK

    TORONTO, Oct. 8, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce its participation at the BMO & TMX Hemp & Medical Cannabis Conference, taking place in in London, UK on October 16, 2019. Alvaro Torres, Khiron CEO and director will present at the conference, and Franziska Katterbach, Khiron Chief Legal Officer (Europe) will participate in a regulatory panel. The Company will also be available for pre-scheduled one-on-one meetings during the conference.

  • CNW Group

    Khiron to Present and Host Attendees at First MJBizDaily Latin American Cannabis Symposium

    TORONTO, Sept. 26, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that the Company will sponsor and participate in MJBizDaily's first Latin American Cannabis Symposium taking place September 30 - October 1 in Bogotá, Colombia. Khiron will be featured prominently throughout the two-day symposium hosting networking events, showcases, and participating in panel presentations by key members of the Company's leadership team.

  • Khiron Secures Approval to Sell Three More CBD Wellness Products
    CNW Group

    Khiron Secures Approval to Sell Three More CBD Wellness Products

    TORONTO, Sept. 25, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that the Company has received approval from INVIMA, Colombia's health agency, to sell 3 additional Kuida® CBD skin care products. This expands on the 7 products currently available at retail and online in Colombia, with first sales of the newly approved product expected in Q4.

  • Newsfile

    Khiron CEO Alvaro Torres Talks Trailblazing in Colombia and Expanding Operations

    Toronto, Ontario--(Newsfile Corp. - September 18, 2019) - Capital 10X President Evan Veryard sits down with Khiron Life Sciences (TSXV: KHRN) CEO Alvaro Torres.They discuss Khiron's Colombian operations, expansion plans, and whether Khiron is on track to meet analyst expectations.Cannot view this video? Visit:https://capital10x.com/khiron-khrn-ceo-alvaro-torres-colombia-operations/For more information, please contact:Capital 10XEvan Veryard, President416-571-9037To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47907

  • CNW Group

    /R E P E A T -- Live Investor Conference & Webinar: Cannabis Industry Companies Present September 12th/

    Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Sept. 6, 2019 /CNW/ - Virtual Investor Conferences and KCSA Strategic Communications today announced ...

  • Khiron Initiates Construction of Cultivation and Processing Facility in Uruguay, Expanding Multi-Jurisdiction and Export Capacity
    CNW Group

    Khiron Initiates Construction of Cultivation and Processing Facility in Uruguay, Expanding Multi-Jurisdiction and Export Capacity

    TORONTO, Sept. 4, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that it has commenced construction of a 9,800 m2 (105,486 sq.ft) cultivation and processing facility in Juan Lacaze, Uruguay. With a production capacity of 17 tons per year, the Company's investment in this state-of-the-art facility represents a significant increase in Khiron's total production capacity, strengthening its ability to export and supply cannabis to key international markets, including Brazil and Europe.

  • CNW Group

    Khiron Secures Exclusive Endorsement from The Colombian Association of Gerontology and Geriatrics

    Seniors identified among the fastest growing adopters of medical cannabis (Source: University of Colorado ) Over 1 million patients in Colombia are elderly and suffer from chronic pain, anxiety, depression ...

  • CNW Group

    Khiron Life Sciences Reports Second Quarter Fiscal 2019 Financial Results

    Expands distribution for Kuida cosmeceutical brand, signing distribution agreements with Fedco, Linio, Cafam – large consumer distribution channels in Colombia. Subsequent to the quarter signed distribution agreement with Grupo Exito, one of South America's market leading retail groups. Completed construction and commenced operations of cultivation, extraction, and analysis facilities near Ibague, Colombia.

  • CNW Group

    Khiron Provides Progress Update on Fully Operational and GMP Compliant Colombian Lab Facilities

    State-of-the-art, 14,000 square foot GMP compliant cannabis extraction lab and ISO 17025 compliant cannabis testing lab includes full capabilities in Ultra high and High performance liquid chromatography ...

  • CNW Group

    Khiron Announces DTC Eligibility, Increasing Access for U.S. Investors

    TORONTO, Aug. 20, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that its shares have received Depository Trust Company (DTC) full-service eligibility in the United States. DTC eligibility is expected to simplify the process of trading and transferring of the Company's common shares in the United States.

  • CNW Group

    Khiron Provides Clarification of August 12, 2019 News Release

    TORONTO, Aug. 14, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, wishes to clarify specific disclosure relating to the news release disseminated by the Company on August 12, 2019. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.

  • CNW Group

    Khiron Boosts European Expansion With Key Executive Appointments

    Experienced capital markets leader and cannabis industry executive Tejinder Virk is appointed President of Khiron Europe Accomplished cannabis legal expert Franziska Katterbach joins Company as Chief Legal ...

  • CNW Group

    Khiron Launches Revenue-Generating Pilot Program With Top Colombian Health Insurance Provider

    Four-month pilot program with EPS SURA represents first step towards an integrated healthcare system for priority neurological pathologies EPS SURA is Colombia's leading insurance provider and an affiliate ...

  • CNW Group

    Khiron Signs Kuida Distribution Agreement with Grupo Éxito, South America's Market Leading Retail Group

    Grupo Éxito has a multinational retail presence in Colombia, Brazil, Argentina and Uruguay and operates 1,533 stores. Kuida to be introduced as key addition to the retailer's cosmetics products category, with experience centres and consultants in each Éxito WOW store to support sales and brand awareness.

  • Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America
    CNW Group

    Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America

    Khiron receives conditional TSXV approval for Latin American joint venture with Dixie Brands and U.S. distribution and sale of Kuida cosmeceutical line Conditional approval subject only to receipt of customary ...

  • CNW Group

    Khiron Provides Update on Canapalife Group Transaction

    TORONTO, Aug. 1, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, today provided an update on the Company's previously announced non-binding LOI with Canapalife Group. The Company confirms the expiry of the LOI and that the parties have mutually agreed not to proceed with the proposed transaction. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.

  • CNW Group

    Khiron Begins Pre-clinical Medical Cannabis Studies with Leading Academic Institutes in Uruguay

    Patient-focused studies advance progress towards global clinical trials on Khiron strains to treat inflammation, oxidative and nervous system disorders Co-sponsored with Uruguay government using Company ...